Suchen
Takeda Pharmaceutical Co Ltd
TAKZur Watchlist hinzufügen
15.720USD
-0.120-0.76%
Handelsschluss 06/24, 16:00（ET）Kurse um 15 Minuten verzögert
50.21BMarktkapitalisierung
40.98KGV TTM
mehr Informationen über Takeda Pharmaceutical Co Ltd Unternehmen
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Takeda Pharmaceutical Co Ltd Informationen
BörsenkürzelTAK
Name des UnternehmensTakeda Pharmaceutical Co Ltd
IPO-datumJun 21, 2085
CEOWeber (Christophe)
Anzahl der mitarbeiter47455
WertpapierartDepository Receipt
GeschäftsjahresendeJun 21
Addresse4F
StadtCHUO-KU
BörseNASDAQ OMX NASDAQ Basic NYSE
LandJapan
Postleitzahl103-8668
Telefon81332782111
Websitehttps://www.takeda.com/
BörsenkürzelTAK
IPO-datumJun 21, 2085
CEOWeber (Christophe)
Führungskräfte von Takeda Pharmaceutical Co Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
7.60K
--
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
--
--
Mr. Ian T. Clark
Mr. Ian T. Clark
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
7.60K
--
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Takeda Pharmaceutical Co Ltd?
Die fünf größten Anteilseigner von Takeda Pharmaceutical Co Ltd sind: Dr. John M. Maraganore, Ph.D.
Wie viele Institutionen halten Anteile an Takeda Pharmaceutical Co Ltd (TAK)?
Mit Stand vom 2026Q1 halten 637 Institutionen Anteile an Takeda Pharmaceutical Co Ltd, mit einem Gesamtmarktwert von etwa 85.31M, was 2.70% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -8142483.00 gestiegen.
Was ist die größte Einnahmequelle von Takeda Pharmaceutical Co Ltd?
Am 2026Q1 erzielte das Geschäft mit Gastrointestinal diseases für Takeda Pharmaceutical Co Ltd den höchsten Umsatz in Höhe von 385.81B, was 32.37% des Gesamtumsatzes entspricht.
